


**In the Claims**

The listing of claims will replace all prior versions and listings of claims in the application.

**Listings of claims**

1. (original) A compound of formula (1):



(1)

A is phenylene or heteroarylene;

n is 0, 1 or 2;

m is 0, 1 or 2;

$R^1$  is independently selected from halo, nitro, cyano, hydroxy, carboxy, carbamoyl, *N*-(1-4C)alkylcarbamoyl, *N,N*-((1-4C)alkyl)<sub>2</sub>carbamoyl, sulphamoyl, *N*-(1-4C)alkylsulphamoyl, *N,N*-((1-4C)alkyl)<sub>2</sub>sulphamoyl,  $-S(O)_b(1-4C)alkyl$  (wherein b is 0, 1, or 2),  $-OS(O)_2(1-4C)alkyl$ , (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxy, (1-4C)alkanoyl, (1-4C)alkanoyloxy, hydroxy(1-4C)alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy and  $-NHSO_2(1-4C)alkyl$ ;

or, when n is 2, the two  $R^1$  groups, together with the carbon atoms of A to which they are attached, may form a 4 to 7 membered saturated ring, optionally containing 1 or 2 heteroatoms independently selected from O, S and N, and optionally being substituted by one or two methyl groups;

one of  $R^2$  and  $R^3$  is selected from  $R_{Na}$ , and the other is selected from  $R_{Nb}$ ;

$R_{Na}$ : (1-3C)alkyl, halo(1-3C)alkyl, dihalo(1-3)alkyl, trifluoromethyl, hydroxy(1-3C)alkyl, dihydroxy(2-3C)alkyl, cyano(1-3C)alkyl (optionally substituted on alkyl with hydroxy), methoxymethyl, ethoxymethyl, methoxyethyl, methoxymethoxymethyl, dimethoxyethyl, (hydroxy)(methoxy)ethyl, 5- and 6-membered acetals and mono- and di-methyl derivatives thereof, (amino)(hydroxy)(2-3C)alkyl, (aminocarbonyl)(hydroxy)(2-3C)alkyl, (methylaminocarbonyl)(hydroxy)(2-3C)alkyl, (dimethylaminocarbonyl)(hydroxy)(2-3C)alkyl, (methylcarbonylamino)(hydroxy)(2-3C)alkyl, (methylS(O)<sub>p</sub>)(hydroxy)(2-3C)alkyl (wherein p is 0, 1 or 2);

$R_{Nb}$ : (1-4C)alkyl, halo(1-4C)alkyl, dihalo(1-4C)alkyl, trifluoromethyl, hydroxy(1-4C)alkyl, dihydroxy(2-4C)alkyl, trihydroxy(3-4C)alkyl, cyano(1-4C)alkyl (optionally substituted on alkyl

with hydroxy), (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkoxy(1-4C)alkoxy(1-4C)alkyl, di[(1-4C)alkoxy](2-4C)alkyl, (hydroxy)[(1-4C)alkoxy](2-4C)alkyl, 5- and 6-membered acetals and mono- and di-methyl derivatives thereof, (amino)(hydroxy)(2-4C)alkyl, (aminocarbonyl)(hydroxy)(2-4C)alkyl, ((1-4C)alkylaminocarbonyl)(hydroxy)(2-4C)alkyl, (di(1-4C)alkylaminocarbonyl)(hydroxy)(2-4C)alkyl, ((1-4C)alkylcarbonylamino)(hydroxy)(2-4C)alkyl, ((1-4C)alkylS(O)<sub>p</sub>)-(hydroxy)(2-4C)alkyl (wherein p is 0, 1 or 2);

wherein any alkyl or alkoxy group within any group in R<sub>N</sub>A and R<sub>N</sub>B may also optionally be substituted on an available carbon atom with a hydroxy group (provided that said carbon atom is not already substituted by a group linked by a heteroatom);

provided that if R<sup>2</sup> is (1-3C)alkyl or (1-4C)alkyl then R<sup>3</sup> is not (1-4C)alkyl or (1-3C)alkyl;

R<sup>4</sup> is independently selected from halo, nitro, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxy and (1-4C)alkanoyl;

or a pharmaceutically acceptable salt or pro-drug thereof.

2. (original) A compound of formula (1) as claimed in Claim 1, or a pharmaceutically acceptable salt or pro-drug thereof, wherein R<sup>2</sup> is selected from R<sub>Na</sub>, and R<sup>3</sup> is selected from R<sub>Nb</sub>, wherein R<sub>Na</sub> and R<sub>Nb</sub> are as defined in Claim 1.

3. (currently amended) A compound of formula (1) as claimed in Claim 1 ~~or Claim 2~~, or a pharmaceutically acceptable salt or pro-drug thereof, wherein A is phenylene.


4. (currently amended) A compound of formula (1) as claimed in Claim 1, ~~2 or 3~~, or a pharmaceutically acceptable salt or pro-drug thereof, wherein n is 0.

5. (currently amended) A compound of formula (1) as claimed ~~in any one of Claim~~[[s]] 1 ~~to 4~~, or a pharmaceutically acceptable salt or pro-drug thereof, wherein m is 0 or 1.

6. (currently amended) A compound of formula (1) as claimed ~~in any one of Claim~~[[s]] 1 ~~to 5~~, or a pharmaceutically acceptable salt or pro-drug thereof, wherein R<sup>4</sup> is methyl, chloro or fluoro.

7. (currently amended) A compound of formula (1) as claimed ~~in any one of Claim~~[[s]] 1 ~~to 6~~, or a pharmaceutically acceptable salt or pro-drug thereof, wherein R<sub>Na</sub> is selected from (1-4C)alkyl, hydroxy(1-4C)alkyl, and (1-4C)alkoxy(1-4C)alkyl.

8. (currently amended) A compound of formula (1) as claimed in ~~any one of Claim[[s]] 1 to 7,~~ or a pharmaceutically acceptable salt or pro-drug thereof, which is a compound of formula (1A):



wherein  $R^1$  to  $R^4$ ,  $m$  and  $n$  are as defined in ~~any one of claim[[s]] 1 to 7.~~


9. (currently amended) A pro-drug of a compound of formula (1) as claimed in ~~any one of Claim[[s]] 1 to 8,~~ which pro-drug is an in-vivo hydrolysable ester.

10. (original) A pharmaceutical composition which comprises a compound of the formula (1), as claimed in claim 1, or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof, in association with a pharmaceutically-acceptable diluent or carrier.


11–15. (cancelled)

16. (original) A process for the preparation of a compound of formula (1) as claimed in claim 1, which process comprises:

reacting an acid of the formula (2):



or an activated derivative thereof; with an amine of formula (3):



and thereafter if necessary:

- i) converting a compound of the formula (1) into another compound of the formula (1);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

17. (new) A compound of formula (1) as claimed Claim 1, or a pharmaceutically acceptable salt or pro-drug thereof, wherein *m* is 0 or 1 and *R*<sup>4</sup> is methyl, chloro or fluoro.

18. (new) A compound of formula (1), or a pharmaceutically acceptable salt or pro-drug thereof, selected from:

5-chloro-*N*-{(1*R*,2*R*)-1-[[*(2S)*-2,3-dihydroxypropanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;

5-chloro-*N*-{(1*R*,2*R*)-1-[methyl(seryl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide hydrochloride;

*N*-{(1*R*,2*R*)-1-[(*N*-acetylseryl)(methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloro-1*H*-indole-2-carboxamide;

(2*S*)-*N*<sup>1</sup>-((1*R*,2*R*)-2-[[*(5-chloro-1H-indol-2-yl)*carbonyl]amino]-2,3-dihydro-1*H*-inden-1-yl)-2-hydroxy-*N*<sup>1</sup>-methylpentanediamide;

(2*S*)-*N*<sup>1</sup>-((1*R*,2*R*)-2-[[*(5-fluoro-1H-indol-2-yl)*carbonyl]amino]-2,3-dihydro-1*H*-inden-1-yl)-2-hydroxy-*N*<sup>1</sup>-methylpentanediamide;

5-chloro-*N*-{(1*R*,2*R*)-1-[[*(2S)*-2-hydroxy-3-methoxypropanoyl] (methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;

5-fluoro-*N*-{(1*R*,2*R*)-1-[[*(2S)*-2-hydroxy-3-methoxypropanoyl] (methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;

(2*S*)-*N*<sup>1</sup>-((1*R*,2*R*)-2-[[*(5-chloro-1H-indol-2-yl)*carbonyl]amino]-2,3-dihydro-1*H*-inden-1-yl)-2-hydroxy-*N*<sup>1</sup>-methylsuccinamide;

(2*S*)-*N*<sup>1</sup>-((1*R*,2*R*)-2-[[*(5-fluoro-1H-indol-2-yl)*carbonyl]amino]-2,3-dihydro-1*H*-inden-1-yl)-2-hydroxy-*N*<sup>1</sup>-methylsuccinamide;

(2*S*)-2-hydroxy-*N*<sup>1</sup>-{(1*R*,2*R*)-2-[(1*H*-indol-2-ylcarbonyl)amino]-2,3-dihydro-1*H*-inden-1-yl}-*N*<sup>1</sup>-methylsuccinamide;

(2*S*)-2-hydroxy-*N*<sup>1</sup>-methyl-*N*<sup>1</sup>-((1*R*,2*R*)-2-[[*(5-methyl-1H-indol-2-yl)*carbonyl]amino]-2,3-dihydro-1*H*-inden-1-yl)succinamide;

*N*-{(1*R*,2*R*)-1-[[*(2S)*-2-hydroxybutanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-methyl-1*H*-indole-2-carboxamide;

5-fluoro-*N*-{(1*R*,2*R*)-1-[[*(2S)*-2-hydroxybutanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;

*N*-{(1*R*,2*R*)-1-[(2*S*)-2-hydroxybutanoyl](methyl)amino}-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;  
 5-chloro-*N*-{(1*R*,2*R*)-1-[(2*S*)-2-hydroxybutanoyl](methyl)amino}-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;  
*N*-{(1*R*,2*R*)-1-[(2*S*)-2,3-dihydroxypropanoyl](methyl)amino}-2,3-dihydro-1*H*-inden-2-yl}-5-methyl-1*H*-indole-2-carboxamide;  
 5-chloro-*N*-{(1*R*,2*R*)-1-[glycoloyl(2-hydroxyethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;  
 5-chloro-*N*-{(1*R*,2*R*)-1-[(2*S*)-2-hydroxybutanoyl](2-hydroxyethyl)amino}-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide; or  
 5-chloro-*N*-{(1*R*,2*R*)-1-[(2*R*)-2,3-dihydroxypropanoyl](methyl)amino}-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide.

19. (new) A method of producing a glycogen phosphorylase inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1.

20. (new) A method of treating type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1.

21. (new) A method of treating type 2 diabetes in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1.